49 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 Mar 24
Report of Foreign Private Issuer
4:30pm
associated with the ongoing sepsis clinical Phase II trial.
In January 2021, the Company submitted a new grant application to the IIA for reimbursement
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
13 Sep 23
Notice of Annual General Meeting of Shareholders
4:42pm
the Companies Regulations (Rules Regarding Compensation and Expense Reimbursement of External Directors), 2000. For details regarding Mr. Novik’s compensation
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
31 Mar 23
Report of Foreign Private Issuer
4:30pm
to the IIA for reimbursement by the IIA of certain expenses associated with its clinical development program of prevention of cytokine storms and organ
6-K
EX-10.1
njl5nd386 b1y3eiq6
30 Dec 22
Report of Foreign Private Issuer
4:02pm
424B5
4l1o dfzc30u
30 Dec 22
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.1
40g09 a4d
5 Oct 22
Notice of Annual General Meeting of Shareholders
3:00pm
6-K
EX-99.1
5t954 t404j
25 May 22
Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant
8:05am
F-3
lfq11
29 Apr 22
Shelf registration (foreign)
8:14am
6-K
EX-99.1
2igbioi1s 7jenhqp
19 Nov 21
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
0n2kgxk
30 Sep 21
Annual and Extraordinary General Meeting of Shareholders
8:01am
6-K
EX-99.1
os4pv5
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm
6-K
EX-99.1
odhrp5nx5t qpuo6d
28 May 21
Condensed Consolidated Financial Statements
4:33pm
6-K
EX-99.1
ovu 3yz76id
18 May 21
Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis
8:03am
6-K
EX-1.1
upanhzh4
12 Feb 21
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
5:17pm
424B5
xfjbh7 ypmy5dr
10 Feb 21
Prospectus supplement for primary offering
5:22pm